VistaGen CEO to Present Overview of Recent Stem Cell-Based Drug Discovery and Development Advances at Society of Biomolecular Sciences Symposium

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov 8, 2007 - At the Society for Biomolecular Sciences (SBS) Stem Cell Symposium today in Anaheim, California, H. Ralph Snodgrass, Ph.D., President and CEO of VistaGen Therapeutics, Inc., will present an overview of the Company's latest embryonic stem (ES) cell-based drug discovery and development advances. VistaGen is a platform-enabled biopharmaceutical company applying embryonic stem cell technologies to discover, develop and commercialize small molecule drugs and protein therapeutics for diabetes and neurological disorders.

"ES cells provide a clinically relevant biological system that offers a powerful discovery tool for understanding many significant diseases such as cancer, diabetes, stroke, heart disease, Alzheimer's, Parkinson's disease, and other neurological disorders," Dr. Snodgrass will tell his Symposium audience. "The in-vitro differentiation of ES cells offers the potential to develop powerful screens for drug effects, and ultimately for producing novel therapies for these devastating diseases."

The Nov. 7-8 SBS Symposium program is organized around the theme "Back to Pharmacology: Stem Cells and Primary Cells in Drug Discovery." In his presentation, Dr. Snodgrass will focus on four ES cell systems -- pancreatic, cardiovascular, hepatic, and neuronal -- that VistaGen is currently using to help identify and develop novel small molecule drugs and protein therapeutics, as well as for predictive pharmacology and toxicology assays. Dr. Snodgrass' discussion will highlight and demonstrate the broad utility of ES cells as next-generation research tools for drug discovery, drug screening and drug development.

Dr. Snodgrass launched VistaGen in 1998, and has acted as its President and CEO since the company's inception. Prior to founding VistaGen, he served as Chief Scientific Officer for Progenitor, Inc. Dr. Snodgrass earned his Ph.D. from the University of Pennsylvania. He has 14 years' senior biotechnology management experience, and has amassed over 10 years of research experience as a professor at the Lineberger Comprehensive Cancer Center at the University of North Carolina Chapel Hill School of Medicine, and as a member of the Institute for Immunology in Basel, Switzerland. Dr. Snodgrass is a past board member of the Emerging Company Section of the Biotechnology Industry Organization (BIO), inventor of more than 10 issued patents, well published in the fields of immunology, development and stem cell biology, and is recognized as a pioneering expert in stem cell biology and the uses of stem cells as tools for drug discovery.

VistaGen Therapeutics, Inc. is an emerging biopharmaceutical technology leader applying patented embryonic stem cell technologies for predictive toxicology screening and to discover, develop and commercialize new drug and protein therapies for diabetes and neurological disorders, including neuropathic pain, Parkinson's disease and epilepsy. Founded in California in 1998, VistaGen discovers and develops drugs for its own pipeline through internal programs and collaborations with leading research organizations worldwide. VistaGen also leverages its proprietary embryonic stem cell technology platform through strategic collaborations with leading pharmaceutical companies worldwide. More information at www.vistagen.com.

Contact

Media:
Russell Communications Group
Christine Thomas, 310-559-4955, x103
christinethomas@ruscom.com
or
Investors:
Stern Investor Relations, Inc.
Lilian Stern, 212-362-1200
lilian@sternir.com

Posted: November 2007

View comments

Hide
(web1)